Specialist treatment of chronic fatigue syndrome/ME:a cohort study among adult patients in England by Collin, Simon M. & Crawley, Esther
                          Collin, S. M., & Crawley, E. (2017). Specialist treatment of chronic fatigue
syndrome/ME: a cohort study among adult patients in England. BMC Health
Services Research, 17, [488]. https://doi.org/10.1186/s12913-017-2437-3
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1186/s12913-017-2437-3
Link to publication record in Explore Bristol Research
PDF-document
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
RESEARCH ARTICLE Open Access
Specialist treatment of chronic fatigue
syndrome/ME: a cohort study among adult
patients in England
Simon M Collin* and Esther Crawley
Abstract
Background: NHS specialist chronic fatigue syndrome (CFS/ME) services in England treat approximately 8000 adult
patients each year. Variation in therapy programmes and treatment outcomes across services has not been described.
Methods: We described treatments provided by 11 CFS/ME specialist services and we measured changes in patient-
reported fatigue (Chalder, Checklist Individual Strength), function (SF-36 physical subscale, Work & Social Adjustment
Scale), anxiety and depression (Hospital Anxiety & Depression Scale), pain (visual analogue rating), sleep (Epworth,
Jenkins), and overall health (Clinical Global Impression) 1 year after the start of treatment, plus questions about impact
of CFS/ME on employment, education/training and domestic tasks/unpaid work. A subset of these outcome measures
was collected from former patients 2–5 years after assessment at 7 of the 11 specialist services.
Results: Baseline data at clinical assessment were available for 952 patients, of whom 440 (46.2%) provided 1-year
follow-up data. Treatment data were available for 435/440 (98.9%) of these patients, of whom 175 (40.2%) had been
discharged at time of follow-up. Therapy programmes varied substantially in mode of delivery (individual or group)
and number of sessions. Overall change in health 1 year after first attending specialist services was ‘very much’ or
‘much better’ for 27.5% (115/418) of patients, ‘a little better’ for 36.6% (153/418), ‘no change’ for 15.8% (66/418), ‘a little
worse’ for 12.2% (51/418), and ‘worse’ or ‘very much worse’ for 7.9% (33/418). Among former patients who provided 2-
to 5-year follow-up (30.4% (385/1265)), these proportions were 30.4% (117/385), 27.5% (106/385), 11.4% (44/385), 13.5%
(52/385), and 17.1% (66/385), respectively. 85.4% (327/383) of former patients responded “Yes” to “Do you think that
you are still suffering from CFS/ME?” 8.9% (34/383) were “Uncertain”, and 5.7% (22/383) responded “No”.
Conclusions: This multi-centre NHS study has shown that, although one third of patients reported substantial overall
improvement in their health, CFS/ME is a long term condition that persists for the majority of adult patients even after
receiving specialist treatment.
Keywords: Chronic fatigue syndrome, ME, NHS England, Specialist care
Background
Chronic Fatigue Syndrome (CFS), also known as ‘ME’, is
a long-term disabling condition characterised by debili-
tating fatigue of unknown cause, post-exertional malaise,
cognitive dysfunction and disturbed/unrefreshing sleep,
plus other symptoms including muscle and joint pain,
headaches, and dizziness [1]. CFS/ME imposes an im-
mense burden on patients, carers and families [2, 3].
In the UK, adults who attend NHS specialist CFS/ME
services have been ill for a median duration of 3 years,
and half of those employed at the onset of their illness
cease working [4]. A meta-analysis of CFS/ME preva-
lence studies based on clinically-confirmed cases in
several countries gave a prevalence of 0.8% (95% CI
0.2% to 1.3%) [5].
Around 8000 patients are treated annually by NHS
specialist CFS/ME services in England [6]. There are
approximately 50 such services in England, many of
which were established under the CFS/ME Service In-
vestment Programme (2004–2006) [7]. These services
follow guidance provided by the National Institute for
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Health & Care Excellence (NICE), including specific
guidelines for diagnosis, specialist care, and ongoing
management, with an overall patient-centred approach
to treatment [8].
In this study we used initial assessment and patient-
reported outcome data from newly referred and former
patients who attended specialist CFS/ME services in
England to investigate outcomes 1–5 years after initial
assessment by the service. We also collected patient-
level treatment data to describe variation in treatments
across specialist services.
Methods
Study cohort - newly referred patients
Newly referred patients were recruited from 11 specialist
CFS/ME services across England (10 NHS services, 1
registered independent provider) during the period 01/
06/2014 to 30/09/2016. Patients were eligible if they
were ≥18 years old and had a CFS/ME diagnosis made
or confirmed at an initial clinical assessment appoint-
ment in accordance with NICE guidelines [8].
Patient-level data - newly referred patients
At the time or their initial assessment, patients complete
standard questionnaires to obtain quantitative measures
of fatigue (Chalder Fatigue Scale [9] and Checklist
Individual Strength (CIS20-R) [10]), physical function
(RAND SF-36 [11]), general function (Work & Social
Adjustment Scale [12]), mood (Hospital Anxiety &
Depression Scale (HADS) [13]), pain (visual analogue
pain rating scale), daytime sleepiness (Epworth Sleepi-
ness Scale [14]), and sleep problems (Jenkins Sleep Scale
[15]). Patients were also asked about the impact of ill
health on employment, education/training, and unpaid
work (e.g. housework, child care, voluntary work). The
same set of questionnaires was sent to patients by post
or via email (with a link to online versions of the ques-
tionnaires) approximately 12 months after their initial
clinical assessment. At follow-up, patients were also
asked to rate changes in overall health and CFS/ME
(Clinical Global Impression scale), and were asked “Do
you think that you are still suffering from CFS/ME?” Pa-
tients who didn’t respond were contacted by the clinical
team via phone or email on up to 2 further occasions to
elicit a response. Data on treatment received by each pa-
tient were recorded by clinical teams or extracted from
hospital administration databases at the end of the study.
Treatment data included the date, duration and type of
session (group or individual), and the qualification of the
health care professional delivering the session.
Study cohort - former patients
For 7 of the 11 services, random samples of pseudonym-
ous patient identifiers (50–60 per year for the period
2010–2013) were obtained from the CFS/ME National
Outcomes Database (NOD). The CFS/ME NOD is a
centralized repository of clinical assessment and patient-
reported outcome data which were routinely collected
by NHS specialist CFS/ME services across England from
2006 to 2013 for the purpose of service evaluation. Lists
of pseudonymous patient identifiers were sent to the
clinical teams, who then sent out information sheets,
consent forms and questionnaires to patients’ home
addresses.
Patient-level data - former patients
Patients who were treated by specialist services during
the period 2010–2013 had already completed question-
naires to provide measures of fatigue (Chalder Fatigue
Scale [9]) and physical function (RAND SF-36 [11])
when they were first assessed. At follow-up, former pa-
tients were sent these two questionnaires and were
asked about changes in overall health and CFS/ME
(Clinical Global Impression scale), and whether there
had been any changes in employment, education/train-
ing, and their ability to do unpaid work/domestic tasks
and social/leisure activities. They were also asked “Do
you think that you are still suffering from CFS/ME?”
Patient-level treatment data for former patients were not
extracted from medical records.
Statistical analysis
Characteristics of patients who provided follow-up data
were compared with patients who did not respond using
the Chi-squared test for proportions and Kruskal-Wallis
test for continuous measures (both α = 0.05). Changes
(mean differences) in patient-reported measures between
baseline (initial clinical assessment) and 1-year follow-up,
and mean patient-reported measures at baseline and 1- to
5-years follow-up were plotted with 95% confidence inter-
vals. Evidence for associations between baseline comor-
bidities and overall change in health at 2- to 5-year was
assessed using the Chi-squared test (α = 0.05).
Results
One-year follow-up of newly referred patients
Of the 1067 newly referred patients recruited by the 11
services during the study period, 952 (89.2%) had baseline
data and were available for follow-up (Fig. 1). Of these
patients, 771 (81.0%) were female, the median (IQR) age
was 41 (30–50) years, and patients had been ill for 36
(15–84) months. Follow-up data were available for 440/
952 (46.2%) of patients, after an interval of 14.0 (12.5–
16.7) months. Patients who responded tended to be older
(42 (32–51) vs 39 (29–49) years, p = 0.003) and to have a
shorter self-reported duration of illness (26 (12–80) vs 36
(18–84) months, p = 0.02) (Additional file 1: Table S1).
Common CFS/ME-related comorbidities tended to occur
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less frequently among responders vs non-responders: mi-
graine (20.1% (84/417) vs 26.6% (128/482), p = 0.02), de-
pression (28.3% (115/406) vs 41.0% (194/473), p < 0.001),
and anxiety (32.4% (132/407) vs 48.1% (229/476),
p < 0.001). Conversely, at their initial assessment patients
with follow-up were more likely to have been on sick leave
(19.0% (74/389) vs 12.8% (56/438), p = 0.01) and had
shorter working hours per week (21 (8–35) vs 25 (10–37)
hours, p = 0.06). There were no differences between re-
sponders and non-responders in any other characteristics
or measures.
Treatment data were available for 77.9% (742/952) of
patients with baseline data, and for 98.9% (435/440) of
patients with baseline and follow-up data (Table 1). Of
patients who provided follow-up data, 40.2% (175/435)
did so after they had been discharged. The remaining
59.8% (260/435) had not yet completed treatment or had
an open appointment or future follow-up appointment.
Four services (D, E, F, and K) achieved ≥60% follow-up.
Follow-up at the other services ranged from 23% to 52%.
One service (G) had insufficient data (n = 7) for analysis
of outcomes.
At 1 year after initial assessment, there was substantial
variation in total duration of treatment sessions across
services (Fig. 2, Table 1) and in the mix of individual and
group sessions, type of health care professional delivery
the session and/or content of the session (Additional file
1: Table S2). Median total duration of treatment sessions
ranged from 19 to 20 h for services C and K, to 4 h for
services D and J. One service (D) provided only individ-
ual therapy sessions, two services (E and G) provided
mainly (>90%) individual sessions, two services (C and I)
mainly group therapy, and the remainder had ratios of
individual: group therapy between 50:50 and 60:40. The
median duration of therapy sessions was longer among
patients with vs without follow-up data (8 (IQR 5–17) vs
6 (3–12), p < 0.001) and was shorter among patients
who had been discharged vs patients who were still
under treatment at the time of follow-up (6 (3–13) vs 9
(6–19), p < 0.001).
Changes (mean difference) in patient-reported mea-
sures between baseline and follow-up are shown in
Fig. 3 and Table 2. There was evidence (p < 0.05) of
reduction in fatigue on the Chalder Fatigue Scale
across all services, with some variation in size of
effect. Changes in other outcome measures tended to
indicate beneficial effects of treatment, particularly in
general function (Work and Social Adjustment Scale),
depression, sleep (daytime sleepiness and sleep problems)
and concentration and motivation (CIS20R). Evidence for
improvements in physical function (SF36), pain, anxiety,
and activity (CIS20R) was weaker and less consistent
across the services.
Overall, 18% (71/394) of patients reported returning to
work or increasing working hours since first attending a
specialist service, whilst 30% (118/394) reported having
ceased working or reduced hours because of CFS/ME
and 47% (186/394) reported no change (Table 3). In-
creased ability to perform unpaid work and domestic
tasks was reported by 35% (129/372) of patients, reduced
ability by 34% (127/372), and no change by 29% (109/
372). Similarly, 35% (139/397) of patients reported being
able to do more social and leisure activities, 36% (143/
397) reported being less able, and 26% (102/397) re-
ported no change. Only 5% (11/240) reported returning
to, or increasing hours of education/training, whilst 13%
(31/240) ceased or reduced their hours and 79% (189/
240) reported no change.
Fig. 1 Flowchart showing recruitment, data availability and 1-year follow-up of adult patients across CFS/ME specialist services
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Fig. 3 Changes (mean difference with 95% CI) in patient reported outcome measures between initial assessment and 1-year follow-up across
CFS/ME specialist services
Fig. 2 Box chart showing total duration of all treatment sessions (individual face-to-face, individual telephone/internet or group) across CFS/ME
specialist services
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Overall changes in health were reasonably consist-
ent across the specialist services, with 28% (115/418)
reporting their health as much better or very much
better, 65% (270/418) reporting little or no change,
and 8% (33/418) reporting much worse or very much
worse health (Table 4, Fig. 4). Of those reporting little
or no change, the majority said that they were ‘a little
better’ (36.6% (153/418)), with 15.8% (66/418) indicat-
ing ‘no change’ and 12.2% (51/418) a slight deterior-
ation. Similar proportions were observed in response
to the question “Overall, how much do you feel your
CFS/ME has changed since you first came to the
service?” In response to the question “Do you think
that you are still suffering from CFS/ME?” 87% (341/391)
responded “Yes”, 3% (11/391) “No” and 10% (39/391) were
“Uncertain”. Of those who responded “Yes”, 23% (78/339)
also said that their overall health was much or very much
better, compared with 82% (9/11) of those who responded
“No” and 58% (21/36) of those who were “Uncertain”.
Changes (mean difference) in patient-reported mea-
sures between baseline and follow-up for each level of
overall improvement in health are provided as supple-
mentary information (Additional file 2: Figure S1 and
Additional file 1: Table S3).
Long-term (2- to 5-year) follow-up of former patients
Seven of the specialist services attempted to contact ran-
dom samples of former patients who were assessed and
treated in 2010, 2011, 2012 or 2013 (total N = 1265),
and long-term follow-up questionnaires were returned
by 30% (385/1265) of these patients (Fig. 5). Baseline
characteristics (at time of assessment) were the same in
patients who did vs did not respond, except that patients
who responded tended to be older (43 (33–51) vs 38
(30–47) years, p < 0.001) (Additional file 1: Table S4),
and less likely to have presented with comorbid depres-
sion (26.6% (89/335) vs 34.8% (247/709), p = 0.008).
Otherwise, there were no differences between re-
sponders and non-responders in any other baseline char-
acteristics or measures. There was no difference between
the two groups in their responses to the Clinical Global
Impression question “Overall, how much do you feel
your health has changed since you first came to the
CFS/ME service?” at 1 year follow-up, with 32% (84/263)
of non-responders vs 38% (84/223) of responders indi-
cating that they were very much or much better, 58%
(153/263) vs 56% (124/223) reporting little or no change,
and 10% (26/263) vs 7% (15/223) indicating that they
were very much or much worse (p = 0.26).
Patient-reported measures of fatigue and physical
function showed no overall change from 1 year follow-
up onwards (Table 5, Fig. 6), but stratification by re-
sponses to the Clinical Global Impression questionnaire
at 2 to 5 years post-assessment showed that 30–40% of
patients improved from 1 year onwards, 40–60% expe-
rienced little or no change, and 20–25% deteriorated
(Fig. 6). Over the 2–5 year follow-up period, 24% (88/
372) of former patients reported being able to return to
work or increase their working hours, 12% (29/238)
returned to, or increased their hours of, education, 36%
(132/365) increased unpaid work and domestic tasks,
and 35% (133/382) increased their social and leisure activ-
ities (Table 6). Conversely, 27% (102/372), 13% (29/238),
32% (117/365), and 39% (149/382) reported stopping or
reducing paid work, education/training, unpaid/domestic
work, and social/leisure activities, respectively.]
Approximately half of former patients (52.5% (202/385))
reported little or no overall change in their health (of
whom half said that they were a little better), one third
(30.4% (117/385)) said that they were very much or much
better, and 17% (66/385) rated their health as very much
or much worse. The majority of former patients (85%
(327/383)) responded affirmatively to the question “Do
you think that you are still suffering from CFS/ME?”, 6%
(22/383) said “No”, and 9% (34/383) were “Uncertain”. Of
those who responded “Yes”, 23% (74/327) also said that
their overall health was much or very much better, com-
pared with 95% (21/22) of those who responded “No” and
62% (21/34) of those who were “Uncertain”.
Overall change in health at 2- to 5-year follow-up was
associated with comorbid fibromyalgia (p = 0.005) and de-
pression (p = 0.02) recorded at the patient’s baseline clinical
assessment, but was not associated with comorbid anxiety,
migraine, or irritable bowel syndrome. Very much or much
better health was reported by 15.7% (13/83) vs 34.4%
(86/250) of patients who did vs did not have comorbid
fibromyalgia, and by 22.5% (20/89) vs 32.1% (79/246) of
patients with vs without comorbid depression. Very
much or much worse health was reported by 21.7%
(18/83) vs 14.8% (37/250) of patients with vs without
fibromyalgia, and by 25.8% (23/89) vs 13.4% (33/246) of
patients with vs without comorbid depression.
Discussion
This study has described substantial variation in total
therapy time for adult patients attending NHS specialist
CFS/ME services in England. Changes in patient-
reported outcome measures approximately one year
after patients’ initial assessments demonstrated clear
improvement, particularly in fatigue, general function,
depression, sleep, concentration, and motivation. At one
year follow-up, one quarter of patients rated their overall
health as very much or much better, the majority (two
thirds) reported little or no change (of whom half had
improved slightly), and <10% reported much or very
much worse health. Just under 90% of patients said that
they were still suffering from CFS/ME, although one
quarter of these also said that their overall health was
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very much or much better. Among former patients who
returned long term (2- to 5-year) follow-up question-
naires, one third rated their overall health as very much
or much better, half reported little or no change, 17%
reported substantial deterioration, and 85% said that
they were still suffering from CFS/ME.
Strengths and limitations
The main strength of our study is that a large cohort of
patients was recruited from NHS specialist services in
England, all of which follow NICE guidelines for the
diagnosis and management of CFS/ME [8]. This should
ensure that the patients in our study have been diagnosed
with CFS/ME according to the same criteria, namely
persistent or recurrent debilitating fatigue of ≥4 months’
duration which is not lifelong, or the result of ongoing
exertion, or alleviated by rest, or explained by other
conditions, and which results in a substantial reduction
in activity. We measured patient-reported outcomes
using standardised questionnaires which are used rou-
tinely in clinical practice, and which have also been
used widely in epidemiological research [16, 17].
The main limitation of this study is the substantial loss
to follow-up, both among the newly referred patients
and among the former patients. Although 12-month
follow-up of newly referred patients was 74% at one
service and 60–65% at three services, follow-up at the
other seven services ranged from 23 to 52%. Long-term
follow-up of former patients was 30%. These losses to
follow-up mean that all of our analyses must be inter-
preted with the caveat that bias could be introduced in
either direction if patients who were more (or less) likely
to recover were more (or less) likely to return their
questionnaires. Another limitation is that we measured
outcomes in newly-referred patients at a fixed time after
their initial assessment, with 60% of patients still being
under treatment at time of follow-up. Also, measure-
ment of outcomes at a single time point is not ideal for
an illness which can fluctuate over time.
Comparison with previous literature
The best comparators for our real world results are the
results reported by the PACE trial of cognitive behaviour
therapy (CBT) and graded exercise therapy (GET) for
adults with CFS/ME. The PACE trial showed a reduction
Fig. 4 Clinical Global Impression responses at 1-year follow-up across CFS/ME specialist services
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(in the CBT and GET arms) in mean fatigue (on the
Chalder Scale) from 28 points at randomisation to 20
points at 12 months [18], followed by a slight (1–2
point) further reduction at 31 (IQR 30–32) months
follow-up [19]. This is very similar to the trend observed
in our data. PACE reported larger improvements in
physical function (from 37 to 39 points at baseline to 58
points at 12 months followed by slight or no further
change at long-term follow-up) than observed in our
study, a difference between trial and real world outcomes
which we found previously in an analysis of routinely-
collected data [20]. The proportions of PACE trial partici-
pants (in the CBT and GET arms) who rated their overall
health as very much or much better at 12 and 31 months
were 41% and 42–48%, respectively, compared with 28%
and 30% in our study (at 12 months and 2–5 years).
We cannot say whether these differences represent
better long term outcomes attributable to the treatment
programmes in the trial, the effect of the majority of
patients in our study still being under treatment, or bias
in our study if patients who improved were more likely
to be lost to follow up. Participants in the CBT and GET
arms of the PACE trial received (median (IQR)) 14 (12–15)
individual CBT sessions (86% face-to-face, 14% by tele-
phone) and 13 (12–14) individual GET sessions (94% face-
to-face, 6% by telephone) respectively, and one fifth went
on to receive further therapy sessions after the trial ended.
Only four services in our study (C, F, G, and K) provided a
similar number of therapy sessions, with considerable vari-
ation in follow-up and outcomes. One of these services (F)
provided 12 (6–13) therapy sessions and follow-up was
obtained from 74% (58/78) of patients of whom 40%
(23/57) rated their overall health as very much or much
better. In this service, the ratio of individual: group
therapy was 50:50, which suggests scope for even better
cost-effectiveness than reported in the PACE trial [21].
Implications for clinical practice and future research
Pointers for future research are perhaps given by some
of the between-service differences in outcomes. For ex-
ample, patients who were treated by service D (with
60% follow-up) reported particularly good improve-
ments in physical function despite receiving a relatively
small number (median 7 (IQR 3–8)) of (mostly GET)
sessions - this service also delivered 28% of therapy
sessions via telephone. Service K (with 65% follow-up)
obtained similar improvements in physical function by
means of a larger number of sessions (12 (9–13), mostly
with an occupational therapist) of which 65% were
group sessions. These similarities in outcomes and dif-
ferences in modes of delivery merit further exploration,
and could form the basis of future randomised controlled
trials. Similarly, treatments in our study were delivered by
multidisciplinary teams variously comprising specialist
clinicians, clinical psychologists, occupational therapists,
and physiotherapists, which highlights the lack of an evi-
dence base regarding the optimal mix of health care profes-
sionals required to deliver the most cost-effective service.
Factorial trials are particularly suited to addressing multiple
questions about content and delivery of treatments [22],
Fig. 5 Flowchart showing follow-up of former patients treated 2–5 years previously by CFS/ME specialist services
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Table 5 Median (IQR) fatigue and physical function at baseline (assessment) and at 1- to 5-year follow-up among patients treated
by CFS/ME specialist services
Baseline 1 year 2 years 3 years 4 years 5 years
Chalder Fatigue
Scale (range 0–33)
All former patients in sample 28 (24–31),
n = 1265
21 (13–26),
n = 516
20 (15–27),
n = 80
21 (15–26),
n = 83
20 (16–26),
n = 106
21 (14–28),
n = 99
Patients who reported very
much or much better overall
health at 2, 3, 4, or 5 years
27 (23–40),
n = 117
16 (11–22),
n = 69
15.5 (11–20),
n = 20
14 (8–19),
n = 22
16 (11–19),
n = 41
11 (11–17),
n = 31
Patients who reported little
or no change in overall
health at 2, 3, 4, or 5 years
27.5 (23–30),
n = 202
22 (16–26),
n = 124
20.5 (15.5–27),
n = 52
22 (18–26),
n = 47
21 (17–24),
n = 47
21 (19–27),
n = 43
Patients who reported very
much or much worse overall
health at 2, 3, 4, or 5 years
27 (33–66),
n = 30
24.5 (19–32),
n = 42
30 (24–32),
n = 8
33 (26–33),
n = 14
30.5 (26–33),
n = 18
31 (25–33),
n = 25
SF36 Physical Function
Subscale (range 0–100)
All former patients in sample 47 (27–67),
n = 1265
52 (32–77),
n = 516
52 (29.5–74.5),
n = 80
52 (27–77),
n = 83
57 (32–82),
n = 106
52 (32–82),
n = 99
Patients who reported very
much or much better overall
health at 2, 3, 4, or 5 years
52 (37–67),
n = 117
72 (52–82),
n = 69
77 (49.5–97),
n = 20
87 (67–97),
n = 22
82 (62–87),
n = 41
87 (72–97),
n = 31
Patients who reported little
or no change in overall
health at 2, 3, 4, or 5 years
47 (32–62),
n = 202
49.5 (32–72),
n = 124
52 (29.5–72),
n = 52
47 (27–67),
n = 47
52 (27–67),
n = 47
52 (32–72),
n = 43
Patients who reported very
much or much worse overall
health at 2, 3, 4, or 5 years
29.5 (17–52),
n = 66
24.5 (12–52),
n = 42
24.5 (7–34.5),
n = 8
17 (2–37),
n = 14
22 (7–47),
n = 18
22 (2–37),
n = 25
Fig. 6 Trends in patient-reported fatigue (Chalder) and physical function (SF36) from initial assessment up to 5 years follow-up among patients
treated by CFS/ME specialist services
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and these could also be designed (by randomising prede-
fined subgroups of patients with specific comorbidities
and/or symptom profiles) to investigate the big question in
CFS/ME treatment, namely why some patients experience
substantial improvement whilst others report little or no
improvement.
Table 6 Change in activities and health across CFS/ME specialist services at 2- to 5-year follow-up
2 years 3 years 4 years 5 years Overall
Paid work (employed/self-
employed) since attending
CFS/ME service
There has been no change
in my employment situation
51.3% (39/76) 45.0% (36/80) 41.8% (43/103) 26.8% (26/97) 41.4% (154/372)
I have been able to return
to work or increase my hours
18.4% (14/76) 17.5% (14/80) 28.2% (29/103) 30.9% (30/97) 23.7% (88/372)
I have stopped working or
reduced my hours because
of CFS/ME
26.3% (20/76) 28.8% (23/80) 22.3% (23/103) 32.0% (31/97) 27.4% (102/372)
I have stopped working or
reduced my hours for other
reasons
4.0% (3/76) 8.8% (7/80) 7.8% (8/103) 10.3% (10/97) 7.5% (28/372)
Education or training since
attending CFS/ME service
There has been no change
in my college/university
attendance
57.8% (26/45) 69.0% (40/58) 69.2% (45/65) 74.1% (43/58) 67.7% (161/238)
I have been able to return to
education/training or increase
my hours
11.1% (5/45) 10.3% (6/58) 15.4% (10/65) 10.3% (6/58) 12.2% (29/238)
I have stopped attending or
reduced my hours because of
CFS/ME
17.8% (8/45) 17.2% (10/58) 7.7% (5/65) 8.6% (5/58) 12.6% (30/238)
I have stopped attending or
reduced my hours for other
reasons
13.3% (6/45) 3.5% (2/58) 7.7% (5/65) 6.9% (4/58) 7.6% (18/238)
Unpaid work and domestic
tasks (childcare, housework,
voluntary work, driving, cooking,
cleaning, etc.) since attending
CFS/ME service
My ability to do unpaid work
and domestic tasks has not
changed
26.3% (20/76) 31.3% (25/80) 24.8% (25/101) 30.1% (28/93) 29.3% (107/365)
I have been able to do more
unpaid work and domestic tasks
29.0% (22/76) 33.8% (27/80) 42.6% (43/101) 38.7% (36/93) 36.2% (132/365)
I do less unpaid work and/or
fewer tasks because of CFS/ME
39.5% (30/76) 35.0% (28/80) 30.7% (31/101) 28.0% (26/93) 32.1% (117/365)
I do less unpaid work and/or
fewer tasks for other reasons
5.3% (4/76) 0.0% (0/80) 2.0% (2/101) 3.2% (3/93) 2.5% (9/365)
Social and leisure activities
(going out, inviting people
over, hobbies, gardening,
travel, exercise, etc.) since
attending CFS/ME service
My ability to do social & leisure
activities has not changed
25.0% (20/80) 34.6% (28/81) 14.2% (15/106) 22.5% (22/98) 23.0% (88/382)
I have been able to do more
social & leisure activities
28.8% (23/80) 32.1% (26/81) 37.7% (40/106) 37.8% (37/98) 34.8% (133/382)
I do fewer social & leisure
activities because of CFS/ME
43.8% (35/80) 32.1% (26/81) 43.4% (46/106) 35.7% (35/98) 39.0% (149/382)
I do fewer social & leisure activities
for other reasons
2.5% (2/80) 1.2% (1/81) 4.7% (5/106) 4.1% (4/98) 3.1% (12/382)
Overall, how much do you feel
your health has changed since
you first came to the CFS/ME
service?
Much better or very much better 25.0% (20/80) 26.5% (22/83) 38.7% (41/106) 31.3% (31/99) 30.4% (117/385)
A little better, no change or a
little worse
65.0% (52/80) 56.6% (47/83) 44.3% (47/106) 43.4% (43/99) 52.5% (202/385)
Much worse or very much worse 10.0% (8/80) 16.9% (14/83) 17.0% (18/106) 25.3% (25/99) 17.1% (66/385)
Overall, how much do you feel
your CFS/ME has changed since
you first came to the CFS/ME
service?
Much better or very much better 18.8% (15/80) 28.9% (24/83) 41.0% (43/105) 35.1% (34/97) 31.4% (120/382)
A little better, no change or a
little worse
73.8% (59/80) 57.8% (48/83) 41.0% (43/105) 43.3% (42/97) 53.1% (203/382)
Much worse or very much worse 7.5% (6/80) 13.3% (11/83) 18.1% (19/105) 21.7% (21/97) 15.5% (59/382)
Do you think that you are
still suffering from CFS/ME?
Yes 86.3% (69/80) 90.4% (75/83) 82.1% (87/106) 82.7% (81/98) 85.4% (327/383)
No 5.0% (4/80) 2.4% (2/83) 6.6% (7/106) 8.2% (8/98) 5.7% (22/383)
Uncertain 8.8% (7/80) 7.2% (6/83) 11.3% (12/106) 9.2% (9/98) 8.9% (34/383)
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Qualitative research has shown that specialist CFS/ME
services play an important role in patients’ journeys to-
wards improved quality of life [23, 24]. Anecdotally, ser-
vices report overall high patient satisfaction, which may
appear to be at odds with a minority of patients experi-
encing substantial improvement. This apparent paradox
may be explained in part by the difficulty of measur-
ing long-term outcomes in a complex chronic illness
[16, 25], a problem which could perhaps be addressed
by using objective rather than subjective measures
[26]. We might also consider how outcomes in our
study compare with other chronic illnesses, such as
chronic widespread pain, fibromyalgia, arthritis and
multiple sclerosis [22, 27, 28], and with the poor prognosis
for CFS/ME in adults if no specialist treatment is received.
Our qualitative study was set in three of the eleven
services in the present study [23]. It showed that referral
to a CFS/ME specialist service was typically the first posi-
tive step in coming to terms with a life changing contested
illness, with improvement coming about through a
process which included validation of patients’ experiences,
acceptance of change, practical advice and support, and
therapeutic outcomes. Professional support was an im-
portant theme, and we recognize that some of the
between-service differences in outcomes in the present
study may be attributable to therapist effects [29–31].
Conclusions
This multi-centre study in the NHS has shown that
CFS/ME is a long term condition that persists for the
majority of adult patients even after receiving specialist
treatment. Whilst 50–65% experienced little or no
change in their condition 1–5 years after accessing a
specialist service and 10–20% reported a deterioration,
up to 30% of patients reported very much or much bet-
ter health (and the majority of those who experienced
little or no change had improved slightly). Given the ad-
verse impact of CFS/ME on patients and their families,
substantial improvement in 20–30% of the approxi-
mately 8000 patients treated each year by specialist CFS/
ME services in England represents a large individual and
societal benefit, and supports the argument that services
need to be sufficiently resourced to treat promptly all
newly diagnosed patients according to individual need.
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